Effects of arotinolol on exercise capacity and humoral factors during exercise in normal subjects.
A placebo-controlled, double-blind crossover study was undertaken in 10 normal subjects to examine the effects of arotinolol (10 mg bid), a nonselective beta blocker with alpha-blocking activity, on exercise capacity and hormone levels during exercise after a 2-week treatment period. Maximal oxygen uptake (VO2 max) and blood lactic acid concentration (LA) were measured during progressive exercise testing. An exercise intensity equivalent to 4 mmol/l of LA was used for the constant workload exercise test. Humoral factors were measured after 20 minutes of constant workload exercise. The administration of arotinolol significantly decreased systolic blood pressure and heart rate at rest and during exercise, but diastolic blood pressure did not change. No significant difference was found between arotinolol and placebo with regard to VO2 max and maximal workload. Plasma renin activity (PRA), aldosterone (PAC), and norepinephrine (NE) levels at rest and during exercise did not differ between the two treatments. In contrast, plasma epinephrine (EN) levels at rest and during exercise were significantly greater with arotinolol. Atrial natriuretic peptide (ANP) at rest did not differ between the two treatments. However, exercise caused a significant increase in ANP after arotinolol treatment. These findings suggest that arotinolol decreases blood pressure and heart rate without affecting exercise capacity.
Mori
T
T
Department of Internal Medicine, School of Medicine, Fukuoka University, Japan.
Handa
K
K
Terao
Y
Y
Tanaka
H
H
Kiyonaga
A
A
Shindo
M
M
Matsunaga
A
A
Sasaki
J
J
Arakawa
K
K
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000328:Adult; D000450:Aldosterone / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002851:Chromatography, High Pressure Liquid; D004311:Double-Blind Method; D004837:Epinephrine / Q000097:blood; D005080:Exercise Test; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects*; D005082:Physical Exertion / Q000187:drug effects*; D011412:Propanolamines / Q000494:pharmacology*; D011863:Radioimmunoassay; D011897:Random Allocation; D012083:Renin / Q000097:blood
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C024523:arotinolol; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; D012083:Renin; D009638:Norepinephrine; D004837:Epinephrine